1. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother. 2008; 52:24–36.
2. Andrews J, Honeybourne D, Ashby J, Jevons G, Fraise A, Fry P, Warrington S, Hawser S, Wise R. Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. J Antimicrob Chemother. 2007; 60:677–680.
3. Boselli E, Breilh D, Rimmelé T, Djabarouti S, Toutain J, Chassard D, Saux MC, Allaouchiche B. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med. 2005; 33:1529–1533.
4. Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother. 2002; 46:1475–1480.
5. Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R. Intrapulmonary penetration of linezolid. J Antimicrob Chemother. 2003; 51:1431–1434.
6. Rodvold KA. Plasma and intrapulmonary concentrations of oritavancin and vancomycin in normal healthy adults. Abstracts of the 14th European congress of clinical microbiology and infectious diseases. In : 14th European congress of clinical microbiology and infectious diseases; Prague, Czech Republic. Basel, Switzerland: ESCMID;2004. p. 44. Abstract O-254.
7. Mimoz O, Rolland D, Adoun M, Marchand S, Breilh D, Brumpt I, Debaene B, Couet W. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Med. 2006; 32:775–779.
8. Gotfried MH, Shaw J, Benton BM, Krause KM, Goldberg MR, Kitt MM, Barriere SL. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on
in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother. 2008; 52:92–97.
9. Conte JE Jr, Golden JA, Kelley MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents. 2005; 25:523–529.
10. Lamer C, de Beco V, Soler P, Calvat S, Fagon JY, Dombret MC, Farinotti R, Chastre J, Gibert C. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother. 1993; 37:281–286.
11. Lodise TP, Drusano GL, Butterfield JM, Scoville J, Gotfried M, Rodvold KA. Penetration of vancomycin into epithelial lining fluid in healthy volunteers. Antimicrob Agents Chemother. 2011; 55:5507–5511.
12. Nau R, Sörgel F, Prange HW. Lipophilicity at pH 7.4 and molecular size govern the entry of the free serum fraction of drugs into the cerebrospinal fluid in humans with uninflamed meninges. J Neurol Sci. 1994; 122:61–65.
13. Fernández A, Cabellos C, Tubau F, Maiques JM, Doménech A, Ribes S, Liñares J, Viladrich PF, Gudiol F. Experimental study of teicoplanin, alone and in combination, in the therapy of cephalosporin-resistant pneumococcal meningitis. J Antimicrob Chemother. 2004; 55:78–83.
14. Barcia-Macay M, Seral C, Mingeot-Leclercq M, Tulkens PM, Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against
Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother. 2006; 50:841–851.
15. Chambers HF, Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother. 1990; 34:510–514.
16. Laue H, Valensise T, Seguin A, Hawser S, Lociuro S, Islam K. Effect of human plasma on the antimicrobial activity of iclaprim
in vitro. J Antimicrob Chemother. 2007; 60:1388–1390.
17. Koch-Weser J, Sellers EM. Binding of drugs to serum albumin (first of two parts). New Engl J Med. 1976; 294:311–316.
18. Craig WA, Suh B. Protein Binding and the antimicrobial effects: methods for the determination of protein binding. In : Lorian V, editor. Antibiotics in laboratory medicine. Baltimore, MD: Williams and Wilkins;1996. p. 367–402.
19. Wise R. Protein binding of beta-lactams: the effects on activity and pharmacology particularly tissue penetration. I. J Antimicrob Chemother. 1983; 12:1–18.
20. Silverman JA, Mortin LI, VanPraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant:
in vitro modeling and clinical impact. J Infect Dis. 2005; 191:2149–2152.
21. Herkner H, Műller MR, Keischitz N, Mayer BX, Frossard M, Joukhadar C, Klein N, Lackner E, Müller M. Closed-chest microdialysis to measure antibiotic penetration into human lung tissue. Am J Respir Crit Care Med. 2002; 165:273–276.
22. Hutschala D, Skhirtladze K, Zuckermann A, Wisser W, Jaksch P, Mayer-Helm BX, Burgmann H, Wolner E, Müller M, Tschernko EM. In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. Antimicrob Agents Chemother. 2005; 49:5107–5111.
23. Tomaselli F, Dittrich P, Maier A, Woltsche M, Matzi V, Pinter J, Nuhsbaumer S, Pinter H, Smolle J, Smolle-Jüttner FM. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by
in vivo microdialysis. Br J Clin Pharmacol. 2003; 55:620–624.
24. Zeitlinger MA, Traunmüller F, Abrahim A, Müller MR, Erdogan Z, Müller M, Joukhadar C. A pilot study testing whether concentrations of levofloxacin in interstitial space fluid of soft tissues may serve as a surrogate for predicting its pharmacokinetics in lung. Int J Antimicrob Agents. 2007; 29:44–50.
25. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993; 37:1073–1081.
26. Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm. 2000; 57:Suppl 2. S4–S9.
27. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with
Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004; 43:925–942.